Screening of JAK2 V617F Mutation in Multiple Myeloma

Leukemia - United Kingdom
doi 10.1038/sj.leu.2404332
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma

Indian Journal of Hematology and Blood Transfusion
Hematology
2015English

Successful Treatment With Azacitidine for the Simultaneous Occurrence of Multiple Myeloma and Acute Myeloid Leukemia With Concomitant Del(5q) and the JAK2 V617F Mutation

Annals of Hematology
MedicineHematology
2017English

Ras Oncogene Mutation in Multiple Myeloma

Journal of Experimental Medicine
MedicineAllergyImmunology
1989English

JAK2-V617F-mediated Signalling Is Dependent on Lipid Rafts and Statins Inhibit JAK2-V617F-dependent Cell Growth

British Journal of Haematology
Hematology
2012English

The Frequency of JAK2 V617F Gen Mutation and Its Associations With Whole Blood Count Parameters

Turkish Journal of Biochemistry
BiochemistryClinical BiochemistryMolecular Biology
2014English

Absence of the JAK2 V617F Activating Mutation in Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Evaluation on Thrombotic Events Frequency in JAK2 V617F Positive Patients

Journal of Hematology & Thromboembolic Diseases
2017English

Icaritin Suppresses Multiple Myeloma, by Inhibiting IL-6/JAK2/STAT3

Oncotarget
Oncology
2015English

A Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report

SN Comprehensive Clinical Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy